Epocrates targets OTCs with reference module

Share this article:
Epocrates targets OTCs with reference module
Epocrates targets OTCs with reference module
Epocrates introduced a new OTC drug module that will allow clinicians to access the latest information for hundreds of brand name OTC drugs from their iPhone, BlackBerry, Palm or Windows device.

Officials at the San Mateo, CA-based company note that OTC products with multiple active ingredients are very common since patients often have many symptoms to treat at once. The OTC reference module will allow physicians and pharmacists to identify specific ingredients in combination products, such as for cough and cold. For instance, an antihistamine could cause additional drowsiness or interact with blood pressure medicines.

A physician using Epocrates software could quickly find the single offending agent causing a product's contraindication, adverse reaction or drug interactions and identify an alternative.

Health providers may also use the software to uncover: drug interactions between OTC and prescription medications; safe products for pregnant women and sugar-free products for diabetics; products covered by Medicaid and select health plans for eligible patients; and medications by class such as analgesics or expectorants (cough syrups). 

Epocrates is a provider of clinical information and decision support tools to healthcare professionals and currently has more than 800,000 active subscribers worldwide, including more than one in three US physicians and 40% of US medical students.
Share this article:

Email Newsletters

More in News

Lack of marketing partner delays Afrezza launch

Lack of marketing partner delays Afrezza launch

Afrezza was heralded as one of the most innovative diabetes products of the last decade. So, why hasn't MannKind set a firm launch date for the product?

In sunny world of LASIK marketers, a dark underbelly

In sunny world of LASIK marketers, a dark ...

Last week, the former FDA branch chief who originally approved LASIK machines asked FDA to reconsider its denial last month of his petition to ban these devices.

BMS Q2 sales slip, Eliquis, Yervoy soar

BMS Q2 sales slip, Eliquis, Yervoy soar

The company attributed part of the Eliquis boost to the BMS-Pfizer DTC and education efforts.